Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Annexon, Inc. - common stock (NQ:ANNX)

2.410 -0.030 (-1.23%)
Streaming Delayed Price Updated: 1:17 PM EDT, Jun 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Annexon, Inc. - common stock

< Previous 1 2 3 Next >
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting
From Annexon Biosciences
Via GlobeNewswire
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
From Annexon Biosciences
Via GlobeNewswire
Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual Meeting
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon Announces Pricing of $125 Million Underwritten Public Offering
From Annexon Biosciences
Via GlobeNewswire
Annexon Announces Proposed Public Offering of Common Stock
From Annexon Biosciences
Via GlobeNewswire
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
From Annexon Biosciences
Via GlobeNewswire
Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data
Call scheduled for Tuesday, June 4, 2024 at 8:30 a.m. ET 
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
Annexon Biosciences to Present at the Bank of America Health Care Conference
From Annexon Biosciences
Via GlobeNewswire
Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting
From Annexon Biosciences
Via GlobeNewswire
Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Turnstone Biologics Appoints William Waddill to its Board of Directors
From Turnstone Biologics Corp.
Via GlobeNewswire
Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference
From Annexon Biosciences
Via GlobeNewswire
Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases
From Annexon Biosciences
Via GlobeNewswire
Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
From Annexon Biosciences
Via GlobeNewswire
Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway
From Annexon Biosciences
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.